-
公开(公告)号：US10201607B2
公开(公告)日：2019-02-12
申请号：US15938961
申请日：2018-03-28
Applicant: GENMAB A/S
Inventor： Esther Breij , David Satijn , Edward Norbert Van Den Brink , Dennis Verzijl , Rob N. De Jong , Paul Parren , Riemke Van Dijkhuizen Radersma
IPC: A61K39/00 , A61K47/68 , C07K16/28 , C07K16/30 , A61K39/395
Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
-
公开(公告)号：US20190030178A1
公开(公告)日：2019-01-31
申请号：US15758520
申请日：2016-09-09
Applicant: GENMAB A/S
Inventor： Steen LISBY , Nancy Cherry WHITING
Abstract: Anti-TF antibody drug conjugate and pharmaceutical compositions comprising the antibody drug-conjugate for use in the treatment of a solid cancer comprising administering to a subject a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an anti-TF antibody drug conjugate once a week for three consecutive weeks followed by a one week resting period without any administration of anti-TF ADC so that each cycle time is 28 days including the resting period.
-
公开(公告)号：US09862769B2
公开(公告)日：2018-01-09
申请号：US13700341
申请日：2011-05-27
Applicant: Bart De Goeij , Simone De Haij , Thilo Riedl , Rene Hoet , Ole Baadsgaard , Jan Van De Winkel , David Satijn , Paul Parren , Aran Frank Labrijn , Joyce Meesters , Janine Schuurman , Edward N. Van Den Brink
Inventor： Bart De Goeij , Simone De Haij , Thilo Riedl , Rene Hoet , Ole Baadsgaard , Jan Van De Winkel , David Satijn , Paul Parren , Aran Frank Labrijn , Joyce Meesters , Janine Schuurman , Edward N. Van Den Brink
IPC: A61K39/395 , C07K16/00 , C07K16/28 , C07K16/32 , A61K39/00
CPC classification number: C07K16/2863 , A61K2039/505 , C07K16/2809 , C07K16/32 , C07K2317/31 , C07K2317/52 , C07K2317/526 , C07K2317/528 , C07K2317/56 , C07K2317/565 , C07K2317/732 , C07K2317/77 , C07K2317/92
Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related anti-body-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
-
公开(公告)号：US09598493B2
公开(公告)日：2017-03-21
申请号：US14592558
申请日：2015-01-08
Applicant: GENMAB A/S
Inventor： Janine Schuurman , Catharina Emanuele Gerarda Havenith , Paul Parren , Jan G. J. Van De Winkel , Denise Leah Williams , Jørgen Petersen , Ole Baadsgaard
IPC: C07K16/28 , G01N33/68 , A61K39/395 , A61K45/06 , A61N5/06 , C07K16/42 , C07K16/46 , G01N33/574 , A61K39/00
CPC classification number: C07K16/2866 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61N5/062 , C07K16/4258 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/56966 , G01N33/57492 , G01N33/6854 , G01N33/6869 , G01N2333/70596 , G01N2333/715 , G01N2333/7155
Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
-
公开(公告)号：US09309315B2
公开(公告)日：2016-04-12
申请号：US11990581
申请日：2006-08-18
Applicant: Paul Parren , Ole Baadsgaard , Denis Alexander
Inventor： Paul Parren , Ole Baadsgaard , Denis Alexander
IPC: A61K39/395 , C07K16/28 , A61K31/37 , A61K41/00 , A61K39/00
CPC classification number: C07K16/2812 , A61K31/37 , A61K39/395 , A61K41/0066 , A61K2039/505 , A61K2300/00
Abstract: The present invention relates to a peptide, such as an antibody, capable of binding to CD4 and use thereof for the mediation of radiation treatment of a clinical condition. The radiation treatment may for instance by treatment with PUVA.
Abstract translation: 本发明涉及能够结合CD4的肽，例如抗体，以及其用于临床病症的放射治疗的介导。 放射治疗可以例如通过用PUVA处理。
-
Patent Agency Ranking
公开(公告)号：US20150368345A1
公开(公告)日：2015-12-24
申请号：US14739771
申请日：2015-06-15
Applicant: Genmab A/S
Inventor： Aran Frank Labrijn , Stefan Loverix , Paul Parren , Jan Van De Winkel , Janine Schuurman , Ignace Laster
IPC: C07K16/28
Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of lgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.
Abstract translation: 本发明涉及抗体的恒定区，特别是1gG4的CH3区，其影响CH3-CH3相互作用强度的位置。 公开了稳定或不稳定这种相互作用的突变。
-
公开(公告)号：US09212230B2
公开(公告)日：2015-12-15
申请号：US12593759
申请日：2008-03-28
Applicant: Janine Schuurman , Tom Vink , Jan Van De Winkel , Aran Frank Labrijn , Rob Aalberse , Marijn Van Der Neut Kolfschote , Paul Parren
Inventor： Janine Schuurman , Tom Vink , Jan Van De Winkel , Aran Frank Labrijn , Rob Aalberse , Marijn Van Der Neut Kolfschote , Paul Parren
CPC classification number: C07K16/468 , C07K16/00 , C07K16/2863 , C07K16/2887 , C07K2317/24 , C07K2317/31 , C07K2317/526 , C07K2317/53 , C07K2319/00
Abstract: The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfidebond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention.
Abstract translation: 本发明涉及用于产生双特异性抗体的离体方法，包括以下步骤：a）提供具有第一结合特异性的第一抗体，其中所述第一抗体包含IgG4样CH3区，b）提供第二抗体 具有不同于所述第一结合特异性的第二结合特异性的抗体，其中所述第二抗体包含IgG4样CH3区，c）在还原条件下将所述第一抗体和第二抗体一起温育，所述还原条件允许核心铰链区域中的半胱氨酸经历二硫键 异构化，和d）获得双特异性抗体。 本发明还涉及通过本发明的方法可获得的双特异性抗体。
-
88.发明授权Heterodimeric antibody Fc-containing proteins and methods for production thereof 有权含有异二聚体抗体的Fc蛋白及其制备方法公开(公告)号：US09150663B2
公开(公告)日：2015-10-06
申请号：US13642253
申请日：2011-04-20
Applicant: Aran Frank Labrijn , Joyce I. Meesters , Ewald T. J. Van Den Bremer , Joost J. Neijssen , Patrick Van Berkel , Bart De Goeij , Tom Vink , Jan Van De Winkel , Janine Schuurman , Paul Parren
Inventor： Aran Frank Labrijn , Joyce I. Meesters , Ewald T. J. Van Den Bremer , Joost J. Neijssen , Patrick Van Berkel , Bart De Goeij , Tom Vink , Jan Van De Winkel , Janine Schuurman , Paul Parren
CPC classification number: C07K16/468 , A61K2039/505 , C07K16/1063 , C07K16/2809 , C07K16/2863 , C07K16/2887 , C07K16/32 , C07K16/40 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/41 , C07K2317/526 , C07K2317/53 , C07K2317/55 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , G01N33/6854
Abstract: Heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.
Abstract translation: 含有异二聚体抗体-Fc的蛋白质，例如双特异性抗体，以及用于产生这种蛋白质的新方法。
-
公开(公告)号：US08961968B2
公开(公告)日：2015-02-24
申请号：US13465181
申请日：2012-05-07
Applicant: Janine Schuurman , Catharina Emanuele Gerarda Havenith , Paul Parren , Jan G. J. Van De Winkel , Denise Leah Williams , Jørgen Petersen , Ole Baadsgaard
Inventor： Janine Schuurman , Catharina Emanuele Gerarda Havenith , Paul Parren , Jan G. J. Van De Winkel , Denise Leah Williams , Jørgen Petersen , Ole Baadsgaard
IPC: C07K16/28 , C07K17/00 , G01N33/577 , A61K51/10 , A61K39/395 , G01N33/68 , A61K39/00
CPC classification number: C07K16/2866 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61N5/062 , C07K16/4258 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/56966 , G01N33/57492 , G01N33/6854 , G01N33/6869 , G01N2333/70596 , G01N2333/715 , G01N2333/7155
Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
-
90.发明申请MODULATION OF COMPLEMENT-DEPENDENT CYTOTOXICITY THROUGH MODIFICATIONS OF THE C-TERMINUS OF ANTIBODY HEAVY CHAINS 审中-公开通过抗体重链C末端修饰来补充依赖性细胞毒性的调节公开(公告)号：US20140271623A1
公开(公告)日：2014-09-18
申请号：US14130580
申请日：2012-07-06
Applicant: Paul Parren , Patrick Van Berkel , Ewald T.J. Van Den Bremer
Inventor： Paul Parren , Patrick Van Berkel , Ewald T.J. Van Den Bremer
CPC classification number: C07K16/18 , C07K16/00 , C07K2317/51 , C07K2317/52 , C07K2317/71 , C07K2317/72 , C07K2317/734 , G01N33/5014 , G01N33/6854
Abstract: Antibody variants having decreased or increased ability to mediate CDC due to modifications at the C-terminus of their heavy chains are described. Methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of said antibodies are also described.
Abstract translation: 描述了由于其重链C末端的修饰而具有降低或增加的CDC介导的CDC的抗体变体。 还描述了产生这种抗体的方法，以及适用于产生所述抗体的核苷酸构建体和宿主细胞。
-
-
-
-
-
-
-
-
-
Search Results
274
records
(took 0.11 seconds)
